Cipla Ltd (NSE: CIPLA) has put production of its child-friendly antiretroviral HIV treatment Lopinavir (ABT-378) on hold as the Indian Government's Health Ministry has failed to clear payments relating to its programme for helping to treat the disease, Pharmafile reported on Monday.
Significant upcoming events at Abbott include the anticipated approval of both Uprima (apomorphine) for erectile dysfunction; a once-a-day version of the company's flagship macrolide antibiotic Biaxin; and the filing for marketing approval of the supplier's next-generation protease inhibitor, ABT-378, in the first half of 2000.